Convalescent plasma as a potential therapy for COVID-19

L Chen, J Xiong, L Bao, Y Shi - The Lancet infectious diseases, 2020 - thelancet.com
L Chen, J Xiong, L Bao, Y Shi
The Lancet infectious diseases, 2020thelancet.com
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which
originated in Wuhan, China, has become a major concern all over the world. The
pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19).
By Feb 22, 2020, this virus has affected more than 77 700 people worldwide and caused
more than 2300 deaths. To date, no specific treatment has been proven to be effective for
SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and …
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). By Feb 22, 2020, this virus has affected more than 77 700 people worldwide and caused more than 2300 deaths. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and extracorporeal membrane oxygenation for the critically ill patients, specific drugs for this disease are still being researched. In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged. 1 However,
thelancet.com